Affordable Access

Publisher Website

Disturbed endothelial cell signaling in tumor progression and therapy resistance.

Authors
  • Fischer, Andreas1
  • Alsina-Sanchis, Elisenda2
  • 1 Department of Clinical Chemistry, University Medical Center Göttingen, Göttingen University, 37075 Göttingen, Germany; German Center for Cardiovascular Research (DZHK), Partner Site Göttingen, Germany. Electronic address: [email protected]. , (Germany)
  • 2 Department of Clinical Chemistry, University Medical Center Göttingen, Göttingen University, 37075 Göttingen, Germany. , (Germany)
Type
Published Article
Journal
Current opinion in cell biology
Publication Date
Feb 01, 2024
Volume
86
Pages
102287–102287
Identifiers
DOI: 10.1016/j.ceb.2023.102287
PMID: 38029706
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Growth of new blood vessels is considered requisite to cancer progression. Recent findings revealed that in addition to inducing angiogenesis, tumor-derived factors alter endothelial cell gene transcription within the tumor mass but also systemically throughout the body. This subsequently contributes to immunosuppression, altered metabolism, therapy resistance and metastasis. Clinical studies demonstrated that targeting the endothelium can increase the success rate of immunotherapy. Single-cell technologies revealed remarkable organ-specific endothelial heterogeneity that becomes altered by the presence of a tumor. In metastases, endothelial transcription differs remarkably between newly formed and co-opted vessels which may provide a basis for developing new therapies to target endothelial cells and overcome therapy resistance more effectively. This review addresses how cancers impact the endothelium to facilitate tumor progression. Copyright © 2023 Elsevier Ltd. All rights reserved.

Report this publication

Statistics

Seen <100 times